Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Terminated · Phase 1 · NCT04204941
Conditions: Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma
At a glance
- Research payments reported, 2025
- $152,258
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 25
About the trial
- Sponsor
- Epizyme, Inc.
- Tested
- Tazemetostat (drug), Doxorubicin HCl (drug)
- Dates
- Started 2019-12-19; completion 2024-06-14
- Results posted
- Not yet
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare for each of the study drug combinations how long participants live without their disease getting worse. The study drug is called tazemetostat. The study will test tazemetostat in combination with …
From ClinicalTrials.gov, last updated 2026-01-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Epizyme, Inc. reported $152,258 in research payments for this study in 2025 (24 payments).
Products named: Tazverik
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mark Agulnik, MD Medical Oncology · Los Angeles, CA
- Sant P. Chawla, M.D. Specialist · Santa Monica, CA
- David A. Liebner, MD Medical Oncology · Columbus, OH
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Oncology Center $91,922
- The Ohio State University Comprehensive Cancer Center $36,835
- City of Hope $22,401
- Sarah Cannon Research Institute $1,100
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.